Previous close | 19.00 |
Open | 18.72 |
Bid | 18.85 x 1500 |
Ask | 18.89 x 8800 |
Day's range | 18.42 - 19.05 |
52-week range | 11.81 - 28.31 |
Volume | |
Avg. volume | 336,191 |
Market cap | 650.761M |
Beta (5Y monthly) | 0.73 |
PE ratio (TTM) | 6.41 |
EPS (TTM) | 2.97 |
Earnings date | 17 Nov 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 32.96 |
EQS-News: MorphoSys AG / Key word(s): ConferenceMorphoSys AG: MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024 09.01.2023 / 07:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germany, January 9, 2023 MorphoSys Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that topline data from the ongoing Phase 3 MA
As every investor would know, not every swing hits the sweet spot. But really big losses can really drag down an...
EQS-News: MorphoSys AG / Key word(s): ForecastMorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability 05.01.2023 / 11:38 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release Planegg/Munich, Germany, January 5, 2023 MorphoSys Reports Preliminary 2022 Monjuvi U.S. Net Product Sales, Provides 2023 Financial Guidance and Reduces Financial Liability Preliminary 2022 Monjuvi U.S. net prod